FCN2

FCN2 encodes Ficolin-2 (L-ficolin), a liver-synthesized, oligomeric serum pattern recognition molecule that activates the lectin complement pathway and functions as an opsonin in innate immunity. The predominant circulating form is a disulfide-stabilized 12-mer (~400 kDa) assembled via a collagen-like triple helix; its fibrinogen-like recognition domains bind acetylated sugars (particularly GlcNAc) and 1,3-β-glucans on microbial surfaces, recruiting MASPs to initiate complement activation and promoting phagocytic uptake by monocytes and neutrophils (PMID:16595153, PMID:11446374). Ficolin-2 binds surface glycolipids of virulent Mycobacterium tuberculosis, blocks epithelial cell infection, and stimulates macrophage pro-inflammatory cytokine and nitric oxide production via JNK signaling in vivo (PMID:24040095). Functional polymorphisms in the FCN2 promoter and fibrinogen-like domain directly modulate serum Ficolin-2 concentration and GlcNAc-binding capacity (PMID:15879437, PMID:17386030).

1. 1995 Low

   Early biochemical work identified a plasma protein (EBP-37) with ficolin-like collagenous and non-collagenous domains that binds elastin and forms disulfide-linked oligomers, establishing the first physical characterization of ficolin family members in human serum.

   Evidence Elastin-Sepharose affinity chromatography, N-terminal sequencing, and immunoblot of human plasma

   PMID:8586615

   Open questions at the time

   • EBP-37 was described as similar but not confirmed identical to the FCN2 gene product
   • No carbohydrate-binding or complement activation was tested
   • Single lab, partial characterization
2. 2000 Medium

   Demonstration that Ficolin-2 functions as an opsonin by binding bacterial surface GlcNAc residues and enhancing phagocytic uptake answered whether ficolins have a direct antimicrobial effector role beyond pattern recognition.

   Evidence Binding assays with Salmonella typhimurium strains differing in surface sugar accessibility, followed by monocyte/PMN phagocytosis assays

   PMID:11446374

   Open questions at the time

   • Opsonophagocytosis shown for a single bacterial species
   • Complement activation downstream of binding was not measured in this study
   • Single lab findings
3. 2005 High

   Genetic dissection of FCN2 revealed that promoter and exon 8 polymorphisms directly regulate serum concentration and GlcNAc-binding capacity, establishing for the first time that natural human FCN2 variation modulates both expression and ligand-recognition function.

   Evidence DNA sequencing, serum ELISA, and GlcNAc binding/recovery assays in a genotyped human cohort

   PMID:15879437

   Open questions at the time

   • Downstream effects of altered binding on complement activation in vivo were not tested
   • No disease association was established in this study
4. 2006 High

   Reconstitution of recombinant Ficolin-2 defined the 12-mer as the major functional oligomer, showed it binds GlcNAc ligands and interacts with MASPs to activate the lectin complement pathway, resolving the quaternary structure–function relationship.

   Evidence Gel filtration, sucrose density gradient ultracentrifugation, mass spectrometry, surface plasmon resonance, and complement activation assays using recombinant Ficolin-2 from CHO cells

   PMID:16595153

   Open questions at the time

   • Crystal structure of the full 12-mer was not solved
   • Relative contributions of different MASP isoforms to Ficolin-2-dependent complement activation were not delineated
5. 2007 High

   Confirmation that Ficolin-2 circulates as a mixture of covalently and non-covalently linked oligomers independent of genotype, alongside replication of promoter SNP effects on serum levels, consolidated the genotype–phenotype framework.

   Evidence Gel-permeation chromatography, SDS-PAGE, Western blot, and TaqMan SNP genotyping in a second cohort

   PMID:17386030

   Open questions at the time

   • Functional consequences of non-covalent vs. covalent oligomeric forms for MASP recruitment were not determined
6. 2013 High

   In vivo mouse challenge experiments using ficolin-A knockout animals and exogenous Ficolin-2 demonstrated that Ficolin-2 binds virulent M. tuberculosis glycolipids, blocks epithelial infection, and activates macrophage JNK/cytokine signaling, extending the effector role beyond opsonization to direct host defense signaling.

   Evidence In vitro binding and infection assays, opsonophagocytosis, C57BL/6J and BALB/c mouse Mtb challenge, ficolin-A KO mice, cytokine and NO measurement

   PMID:24040095

   Open questions at the time

   • The mouse ortholog ficolin-A is not identical to human Ficolin-2; species-specific differences may limit translational inference
   • Whether JNK activation is direct or secondary to complement deposition was not resolved
7. 2013 Medium

   Identification that silica clot activator tubes impair Ficolin-2 binding and lectin-pathway complement activation highlighted that pre-analytical variables affect functional assays, explaining discrepancies across studies.

   Evidence ELISA and complement deposition assays (C4, C3) comparing serum and plasma from different collection tubes

   PMID:23911396

   Open questions at the time

   • Mechanism by which silica specifically inactivates Ficolin-2 was not elucidated
   • Terminal complement complex formation was not detected under the conditions tested

• Key unresolved questions include the high-resolution structural basis of Ficolin-2's dual acetylated-sugar and β-glucan recognition, the precise stoichiometry and selectivity of MASP isoform recruitment by the 12-mer, and the in vivo contribution of Ficolin-2-dependent JNK signaling versus complement activation to anti-mycobacterial defense.
• No full-length crystal or cryo-EM structure of the Ficolin-2 oligomer
• Relative importance of complement-dependent vs. complement-independent effector functions not dissected in human systems
• Causal link between FCN2 polymorphisms and susceptibility to specific infectious diseases not established by Mendelian genetics